A controversial antidepressant, a drug for dementia & more: 4 recent FDA approvals

Four recent drugs or medical devices approved by the FDA since March 1:

Advertisement

1. Esketamine, which will be sold by Johnson & Johnson under the brand name Spravato, is a nasal spray to treat intractable depression. It is controversial due to its potential for abuse.

2. Rivastigmine Transdermal System was approved for the treatment of dementia associated with Alzheimer’s and Parkinson’s disease.

3. Imatinib Mesylate tablets, known by the brand name Stason, is a generic form of Novartis’ Gleevec tablets. The chemotherapy drug slows the growth of cancer cells.

4. Glenmark Pharmaceuticals received final FDA approval for its generic version of Boehringer Ingelheim’s Micardis HCT Tablets. The new generic, telmisartan and hydrochlorothiazide, treats high blood pressure.

More articles on supply chain:
Supplies of bladder cancer drug are dwindling
Washington faces critically low blood supply
Supply chain savings tip of the week: Manage your total transportation spend

Advertisement

Next Up in Supply Chain

  • Becker’s asked supply chain leaders: What’s the most productive partnership supply chain has with another department at your system, and…

  • Medline is laying off 304 workers, according to a notice filed with the state of Illinois and a Nov. 5…

  • As hospitals redefine the role of supply chain leaders to focus on enterprise strategy, digital transformation and resilience, health systems…

Advertisement

Comments are closed.